Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending Oral Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF95245 and Open-label Crossover Study to Investigate Intra-subject Variability, Effect of Food on Lu AF95245, and Metabolic Profile of [14C]-Lu AF95245 in Healthy Young Men
Latest Information Update: 13 May 2020
At a glance
- Drugs Lu AF95245 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lundbeck A/S
Most Recent Events
- 06 May 2020 Status changed from recruiting to discontinued.
- 20 Dec 2019 New trial record